Axillary Sampling as an Alternative Option for Complete Nodal Response in Triple Negative and HER2 Type Breast Cancer Patients after Neoadjuvant Chemotherapy
10.14449/jbd.2020.8.2.121
- Author:
Chan Sub PARK
1
;
Jeeyeon LEE
;
Jin Hyang JUNG
;
Wan Wook KIM
;
Yee Soo CHAE
;
Hye Jung KIM
;
Won Hwa KIM
;
Ji-Young PARK
;
Jee Young PARK
;
Soo Jung LEE
;
Mi Young KIM
;
Jung Dug YANG
;
Joon Seok LEE
;
Ho Yong PARK
Author Information
1. Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
- Publication Type:1
- From:
Journal of Breast Disease
2020;8(2):121-128
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:In patients with locally advanced breast cancer, neoadjuvant chemotherapy is widely used. It has a distinct advantage in the downstaging of the primary tumor and provides important information about treatment response. With its increasing usage, concerns over the appropriate management of the axilla have emerged. In this study, we compared oncological outcomes of conventional axillary lymph node dissection (ALND) over axillary sampling (AS) with radiotherapy (RT) in patients who received neoadjuvant chemotherapy.
Methods:In this retrospective study, we included female patients with triple negative breast cancer (TNBC) and HER2 type breast cancer who underwent breast and axillary surgery after neoadjuvant chemotherapy between May 2011 to December 2016. A total of 89 patients’ medical records were eligible for analysis. We defined AS as removal of at least four axillary lymph nodes located near the sentinel lymph nodes without full exposure of the axillary vein, long thoracic nerve, and thoracodorsal nerve.
Results:The median follow-up period was 47.00 months. The disease-free survival was 69.66 months in the AS with RT group and 69.02 months in the ALND group (p=0.280). The invasive disease-free survival was 75.16 months in the AS with RT group and 78.44 months in the ALND group (p=0.218).
Conclusion:AS with radiotherapy might be a feasible surgical option in patients with TNBC and HER2 type breast cancer after neoadjuvant chemotherapy.
